Rhythm Biosciences Issues New Shares and Lodges Cleansing Notice

Rhythm Biosciences Ltd. ( (AU:RHY) ) just unveiled an announcement.

Rhythm Biosciences has issued 413,793 new ordinary shares on 27 February 2026 and lodged a cleansing notice under section 708A(5)(e) of the Corporations Act, confirming the issuance was made without a disclosure document. The company states it is compliant with its continuous disclosure and financial reporting obligations, and that there is no excluded information requiring disclosure, ensuring the new shares can be freely traded and maintaining regulatory transparency for investors.

The cleansing notice supports Rhythm’s capital management and market activities by enabling efficient share issuance while preserving investor protections under Australian securities law. This administrative step reinforces the company’s adherence to governance standards as it pursues commercialisation of its cancer diagnostics portfolio, which may influence stakeholder confidence and the liquidity of its securities.

The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.20 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.

More about Rhythm Biosciences Ltd.

Rhythm Biosciences Ltd is an Australian medical diagnostics company focused on developing simple, affordable blood tests for the accurate and early detection of cancers. Founded in 2017 and headquartered in Melbourne, it targets improved patient outcomes and reduced cancer burden, working with global partners to commercialise and distribute its diagnostic solutions, including its ColoSTAT colorectal cancer test based on CSIRO research.

Average Trading Volume: 993,151

Technical Sentiment Signal: Buy

Current Market Cap: A$69.21M

See more insights into RHY stock on TipRanks’ Stock Analysis page.